Optic neuritis: guidelines

Curr Opin Neurol. 1995 Feb;8(1):72-6. doi: 10.1097/00019052-199502000-00012.


A major breakthrough in the therapy of demyelinating disease has recently been disclosed by the Optic Neuritis Treatment Trial. Over the past 6 years the trial has accumulated evidence that a high dose of corticosteroids taken to treat patients with an isolated acute attack of optic neuritis reduces the rate at which multiple sclerosis develops over a 2-year period of follow-up. The findings of the trial have had an immediate impact on the neuro-ophthalmic and neurologic community in the USA; therefore, I have focused my review on this important topic.

Publication types

  • Review

MeSH terms

  • Clinical Protocols
  • Disease Progression
  • Humans
  • Methylprednisolone / administration & dosage
  • Methylprednisolone / therapeutic use*
  • Multiple Sclerosis / physiopathology
  • Optic Neuritis / drug therapy*
  • Optic Neuritis / physiopathology
  • Prednisolone / administration & dosage
  • Prednisolone / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Vision Disorders / physiopathology


  • Prednisolone
  • Methylprednisolone